When Bollywood was busy remaking Sholay into OTT web series, IIL quietly remade itself from a generic pesticides seller to a “solution provider.” Monsoons showed up on time but decided to play patchy cricket—helping rice and maize, but bowling out cotton and soybean. Yet, Q1 saw IIL flex premium products, file patents, and brag about farmer connect programs that sound busier than an election rally. Curious? Keep reading—this quarter had herbicides, global tie-ups, and even chilli spice drama.
2. At a Glance
Revenue ₹691 Cr (+5%) – Growth was modest, but better than standing still in a soybean field.
Gross Profit ₹202 Cr (29.2%) – Margins fattened like a buffalo in monsoon.
EBITDA ₹85 Cr (+18%) – Premium products are working harder than interns in August.
PAT ₹58 Cr (+18%) – Bottom line is learning yoga: steady breathing, flexible posture.
B2C Mix 75% – Farmers love branded sprays more than distributors love discounts.
3. Management’s Key Commentary
Quote: “Premium products grew 20%, margins improved to 12%.” (Translation: Generic tail-cutting = profit grooming. Think pesticides with premium haircuts.)
Quote: “Altair, a Nissan herbicide, has gone into 900 villages.” (Translation: Marketing team now knows more farmers than Tinder has profiles.)
Quote: “We launched 12 products last year, and already beat full-year FY25 sales in Q1.” (Translation: Either demand is crazy, or last year’s launch execution was snoozing.)
Quote: “OAT Agrio JV filed 12 patents; first insecticide launch in FY26.” (Translation: Expect Japan-tech pesticides, hopefully priced cheaper than sushi.)
Quote: “South India contributes ~40% of brand business.” (Translation: Chilli sprays = hot margins. Farmers here spray more than Delhiites use deodorant.)
4. Numbers Decoded
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹691 Cr
+5%
Growth was patchy, like monsoons across states.
Gross Profit – Cushion
₹202 Cr
+11.6%
Margins bulked up thanks to premiumization.
EBITDA – Sidekick
₹85 Cr
+18%
Premium products pumped iron for profitability.
EBITDA Margin – Drama
12.3%
+120 bps
Slowly climbing, eyeing 13-14% over 2-3 yrs.
PAT – The Survivor
₹58 Cr
+18%
Bottom line matched premium growth story.
B2C vs B2B – The Split
75% vs 23%
Mix Shift
Farmer brands outshining bulk B2B trade.
Capex – The Builder
₹300 Cr (FY26E)
Ongoing
Dahej Phase 1 done; Sotanala Phase 1 coming.
5. Analyst Questions
Q: EBITDA margin trajectory in 2-3 years? A: Targeting +100 bps annually. (Translation: Think “slow compounding,” not “multibagger.”)
Q: Kaeros merger update? A: FY27 target ₹150–200 Cr revenue. (Translation: Too early now, but we’ve printed brochures already.)
Q: Herbicide demand outlook? A: Cotton/soybean muted, rice/maize hitting highs. (Translation: Some crops drowned, others partying in rain.)
